Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation.

Reiff SD, Mantel R, Smith LL, Greene JT, Muhowski EM, Fabian CA, Goettl VM, Tran M, Harrington BK, Rogers KA, Awan FT, Maddocks K, Andritsos L, Lehman AM, Sampath D, Lapalombella R, Eathiraj S, Abbadessa G, Schwartz B, Johnson AJ, Byrd JC, Woyach JA.

Cancer Discov. 2018 Oct;8(10):1300-1315. doi: 10.1158/2159-8290.CD-17-1409. Epub 2018 Aug 9.

PMID:
30093506
2.

BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor.

Ozer HG, El-Gamal D, Powell B, Hing ZA, Blachly JS, Harrington B, Mitchell S, Grieselhuber NR, Williams K, Lai TH, Alinari L, Baiocchi RA, Brinton L, Baskin E, Cannon M, Beaver L, Goettl VM, Lucas DM, Woyach JA, Sampath D, Lehman AM, Yu L, Zhang J, Ma Y, Zhang Y, Spevak W, Shi S, Severson P, Shellooe R, Carias H, Tsang G, Dong K, Ewing T, Marimuthu A, Tantoy C, Walters J, Sanftner L, Rezaei H, Nespi M, Matusow B, Habets G, Ibrahim P, Zhang C, Mathé EA, Bollag G, Byrd JC, Lapalombella R.

Cancer Discov. 2018 Apr;8(4):458-477. doi: 10.1158/2159-8290.CD-17-0902. Epub 2018 Jan 31.

PMID:
29386193
3.

Novel SF3B1 in-frame deletions result in aberrant RNA splicing in CLL patients.

Agrawal AA, Seiler M, Brinton LT, Mantel R, Lapalombella R, Woyach JA, Johnson AJ, Zhu P, Warmuth M, Yu L, Byrd JC, Smith PG, Blachly JS, Buonamici S.

Blood Adv. 2017 Jun 14;1(15):995-1000. doi: 10.1182/bloodadvances.2017007062. eCollection 2017 Jun 27.

4.

Mitochondria on the move: BMSCs fuel AML energy.

Lapalombella R.

Blood. 2017 Oct 5;130(14):1603-1604. doi: 10.1182/blood-2017-08-798504. No abstract available.

5.

Role and regulation of microRNAs targeting BTK in acute myelogenous leukemia.

Rizzotto L, Lai TH, Bottoni A, Woyach JA, Lapalombella R, Bloomfield CD, Byrd JC, Sampath D.

Leuk Lymphoma. 2018 Jun;59(6):1461-1465. doi: 10.1080/10428194.2017.1376742. Epub 2017 Sep 18. No abstract available.

6.

Targeting BTK through microRNA in chronic lymphocytic leukemia.

Bottoni A, Rizzotto L, Lai TH, Liu C, Smith LL, Mantel R, Reiff S, El-Gamal D, Larkin K, Johnson AJ, Lapalombella R, Lehman A, Plunkett W, Byrd JC, Blachly JS, Woyach JA, Sampath D.

Blood. 2016 Dec 29;128(26):3101-3112. doi: 10.1182/blood-2016-07-727750. Epub 2016 Oct 17.

7.

Two strikes against CLL.

Lapalombella R.

Blood. 2016 Jul 28;128(4):470-1. doi: 10.1182/blood-2016-06-719864. No abstract available.

8.

Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies.

Hing ZA, Fung HY, Ranganathan P, Mitchell S, El-Gamal D, Woyach JA, Williams K, Goettl VM, Smith J, Yu X, Meng X, Sun Q, Cagatay T, Lehman AM, Lucas DM, Baloglu E, Shacham S, Kauffman MG, Byrd JC, Chook YM, Garzon R, Lapalombella R.

Leukemia. 2016 Dec;30(12):2364-2372. doi: 10.1038/leu.2016.136. Epub 2016 May 20.

9.

Interleukin-6 in CLL: accelerator or brake?

Lapalombella R.

Blood. 2015 Aug 6;126(6):697-8. doi: 10.1182/blood-2015-06-650804.

10.

Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia.

Hing ZA, Mantel R, Beckwith KA, Guinn D, Williams E, Smith LL, Williams K, Johnson AJ, Lehman AM, Byrd JC, Woyach JA, Lapalombella R.

Blood. 2015 May 14;125(20):3128-32. doi: 10.1182/blood-2015-01-621391. Epub 2015 Apr 2.

11.

Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation.

Alinari L, Mahasenan KV, Yan F, Karkhanis V, Chung JH, Smith EM, Quinion C, Smith PL, Kim L, Patton JT, Lapalombella R, Yu B, Wu Y, Roy S, De Leo A, Pileri S, Agostinelli C, Ayers L, Bradner JE, Chen-Kiang S, Elemento O, Motiwala T, Majumder S, Byrd JC, Jacob S, Sif S, Li C, Baiocchi RA.

Blood. 2015 Apr 16;125(16):2530-43. doi: 10.1182/blood-2014-12-619783. Epub 2015 Mar 5.

12.

PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL.

El-Gamal D, Williams K, LaFollette TD, Cannon M, Blachly JS, Zhong Y, Woyach JA, Williams E, Awan FT, Jones J, Andritsos L, Maddocks K, Wu CH, Chen CS, Lehman A, Zhang X, Lapalombella R, Byrd JC.

Blood. 2014 Aug 28;124(9):1481-91. doi: 10.1182/blood-2014-05-574830. Epub 2014 Jul 7.

13.

Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma.

Yan F, Alinari L, Lustberg ME, Martin LK, Cordero-Nieves HM, Banasavadi-Siddegowda Y, Virk S, Barnholtz-Sloan J, Bell EH, Wojton J, Jacob NK, Chakravarti A, Nowicki MO, Wu X, Lapalombella R, Datta J, Yu B, Gordon K, Haseley A, Patton JT, Smith PL, Ryu J, Zhang X, Mo X, Marcucci G, Nuovo G, Kwon CH, Byrd JC, Chiocca EA, Li C, Sif S, Jacob S, Lawler S, Kaur B, Baiocchi RA.

Cancer Res. 2014 Mar 15;74(6):1752-65. doi: 10.1158/0008-5472.CAN-13-0884. Epub 2014 Jan 22.

14.

Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells.

Zhong Y, El-Gamal D, Dubovsky JA, Beckwith KA, Harrington BK, Williams KE, Goettl VM, Jha S, Mo X, Jones JA, Flynn JM, Maddocks KJ, Andritsos LA, McCauley D, Shacham S, Kauffman M, Byrd JC, Lapalombella R.

Leukemia. 2014 May;28(5):1158-63. doi: 10.1038/leu.2014.9. Epub 2014 Jan 13. No abstract available.

15.

Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies.

Rafiq S, Siadak A, Butchar JP, Cheney C, Lozanski G, Jacob NK, Lapalombella R, McGourty J, Moledor M, Lowe R, Setter B, Jones J, Flynn JM, Andritsos L, Devine S, Mo X, Jarjoura D, Tridandapani S, Algate P, Byrd JC, Muthusamy N.

MAbs. 2013 Sep-Oct;5(5):723-35. doi: 10.4161/mabs.25282. Epub 2013 Jun 7.

16.

The proteasome inhibitor carfilzomib functions independently of p53 to induce cytotoxicity and an atypical NF-κB response in chronic lymphocytic leukemia cells.

Gupta SV, Hertlein E, Lu Y, Sass EJ, Lapalombella R, Chen TL, Davis ME, Woyach JA, Lehman A, Jarjoura D, Byrd JC, Lucas DM.

Clin Cancer Res. 2013 May 1;19(9):2406-19. doi: 10.1158/1078-0432.CCR-12-2754. Epub 2013 Mar 20.

17.

Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia.

Lapalombella R, Sun Q, Williams K, Tangeman L, Jha S, Zhong Y, Goettl V, Mahoney E, Berglund C, Gupta S, Farmer A, Mani R, Johnson AJ, Lucas D, Mo X, Daelemans D, Sandanayaka V, Shechter S, McCauley D, Shacham S, Kauffman M, Chook YM, Byrd JC.

Blood. 2012 Nov 29;120(23):4621-34. doi: 10.1182/blood-2012-05-429506. Epub 2012 Oct 3.

18.

Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals.

Lapalombella R, Yeh YY, Wang L, Ramanunni A, Rafiq S, Jha S, Staubli J, Lucas DM, Mani R, Herman SE, Johnson AJ, Lozanski A, Andritsos L, Jones J, Flynn JM, Lannutti B, Thompson P, Algate P, Stromatt S, Jarjoura D, Mo X, Wang D, Chen CS, Lozanski G, Heerema NA, Tridandapani S, Freitas MA, Muthusamy N, Byrd JC.

Cancer Cell. 2012 May 15;21(5):694-708. doi: 10.1016/j.ccr.2012.03.040.

19.

The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia.

Herman SE, Lapalombella R, Gordon AL, Ramanunni A, Blum KA, Jones J, Zhang X, Lannutti BJ, Puri KD, Muthusamy N, Byrd JC, Johnson AJ.

Blood. 2011 Apr 21;117(16):4323-7. doi: 10.1182/blood-2010-11-315705. Epub 2011 Mar 4.

20.

Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma.

Alinari L, Yu B, Christian BA, Yan F, Shin J, Lapalombella R, Hertlein E, Lustberg ME, Quinion C, Zhang X, Lozanski G, Muthusamy N, Prætorius-Ibba M, O'Connor OA, Goldenberg DM, Byrd JC, Blum KA, Baiocchi RA.

Blood. 2011 Apr 28;117(17):4530-41. doi: 10.1182/blood-2010-08-303354. Epub 2011 Jan 12.

21.

The clinical application of monoclonal antibodies in chronic lymphocytic leukemia.

Jaglowski SM, Alinari L, Lapalombella R, Muthusamy N, Byrd JC.

Blood. 2010 Nov 11;116(19):3705-14. doi: 10.1182/blood-2010-04-001230. Epub 2010 Jul 7. Review.

22.

FTY720 shows promising in vitro and in vivo preclinical activity by downmodulating Cyclin D1 and phospho-Akt in mantle cell lymphoma.

Liu Q, Alinari L, Chen CS, Yan F, Dalton JT, Lapalombella R, Zhang X, Mani R, Lin T, Byrd JC, Baiocchi RA, Muthusamy N.

Clin Cancer Res. 2010 Jun 15;16(12):3182-92. doi: 10.1158/1078-0432.CCR-09-2484. Epub 2010 May 11.

23.

Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia.

Awan FT, Johnson AJ, Lapalombella R, Hu W, Lucas M, Fischer B, Byrd JC.

Leuk Lymphoma. 2010 Jan;51(1):27-38. doi: 10.3109/10428190903350405. Review.

24.

CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody.

Awan FT, Lapalombella R, Trotta R, Butchar JP, Yu B, Benson DM Jr, Roda JM, Cheney C, Mo X, Lehman A, Jones J, Flynn J, Jarjoura D, Desjarlais JR, Tridandapani S, Caligiuri MA, Muthusamy N, Byrd JC.

Blood. 2010 Feb 11;115(6):1204-13. doi: 10.1182/blood-2009-06-229039. Epub 2009 Dec 2.

25.

Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.

Lapalombella R, Andritsos L, Liu Q, May SE, Browning R, Pham LV, Blum KA, Blum W, Ramanunni A, Raymond CA, Smith LL, Lehman A, Mo X, Jarjoura D, Chen CS, Ford R Jr, Rader C, Muthusamy N, Johnson AJ, Byrd JC.

Blood. 2010 Apr 1;115(13):2619-29. doi: 10.1182/blood-2009-09-242438. Epub 2009 Nov 24.

26.

Gene expression profile of rat left ventricles reveals persisting changes following chronic mild exercise protocol: implications for cardioprotection.

Giusti B, Marini M, Rossi L, Lapini I, Magi A, Capalbo A, Lapalombella R, di Tullio S, Samaja M, Esposito F, Margonato V, Boddi M, Abbate R, Veicsteinas A.

BMC Genomics. 2009 Jul 30;10:342. doi: 10.1186/1471-2164-10-342.

27.

The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia.

Lapalombella R, Gowda A, Joshi T, Mehter N, Cheney C, Lehman A, Chen CS, Johnson AJ, Caligiuri MA, Tridandapani S, Muthusamy N, Byrd JC.

Br J Haematol. 2009 Mar;144(6):848-55. doi: 10.1111/j.1365-2141.2008.07548.x. Epub 2009 Jan 12.

28.

Modulation of paraoxonase 1 and 3 expression after moderate exercise training in the rat.

Romani R, De Medio GE, di Tullio S, Lapalombella R, Pirisinu I, Margonato V, Veicsteinas A, Marini M, Rosi G.

J Lipid Res. 2009 Oct;50(10):2036-45. doi: 10.1194/jlr.M800493-JLR200. Epub 2008 Dec 16.

29.

Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells.

Lapalombella R, Yu B, Triantafillou G, Liu Q, Butchar JP, Lozanski G, Ramanunni A, Smith LL, Blum W, Andritsos L, Wang DS, Lehman A, Chen CS, Johnson AJ, Marcucci G, Lee RJ, Lee LJ, Tridandapani S, Muthusamy N, Byrd JC.

Blood. 2008 Dec 15;112(13):5180-9. doi: 10.1182/blood-2008-01-133108. Epub 2008 Sep 4. Erratum in: Blood. 2009 Oct 15;114(16):3506.

30.

Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia.

Andritsos LA, Johnson AJ, Lozanski G, Blum W, Kefauver C, Awan F, Smith LL, Lapalombella R, May SE, Raymond CA, Wang DS, Knight RD, Ruppert AS, Lehman A, Jarjoura D, Chen CS, Byrd JC.

J Clin Oncol. 2008 May 20;26(15):2519-25. doi: 10.1200/JCO.2007.13.9709. Epub 2008 Apr 21.

31.

Persistence of regenerative myogenesis in spite of down-regulation of activity-dependent genes in long-term denervated rat muscle.

Lapalombella R, Kern H, Adami N, Biral D, Zampieri S, Scordari A, di Tullio S, Marini M.

Neurol Res. 2008 Mar;30(2):197-206. doi: 10.1179/174313208X281091.

PMID:
18397613
32.

A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents.

Lapalombella R, Zhao X, Triantafillou G, Yu B, Jin Y, Lozanski G, Cheney C, Heerema N, Jarjoura D, Lehman A, Lee LJ, Marcucci G, Lee RJ, Caligiuri MA, Muthusamy N, Byrd JC.

Clin Cancer Res. 2008 Jan 15;14(2):569-78. doi: 10.1158/1078-0432.CCR-07-1006.

33.

Partial persistence of exercise-induced myocardial angiogenesis following 4-week detraining in the rat.

Marini M, Falcieri E, Margonato V, Treré D, Lapalombella R, di Tullio S, Marchionni C, Burattini S, Samaja M, Esposito F, Veicsteinas A.

Histochem Cell Biol. 2008 Apr;129(4):479-87. doi: 10.1007/s00418-007-0373-8. Epub 2008 Jan 3.

34.

Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia.

Alinari L, Lapalombella R, Andritsos L, Baiocchi RA, Lin TS, Byrd JC.

Oncogene. 2007 May 28;26(25):3644-53. Review.

PMID:
17530018
35.

Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical.

Zhao X, Lapalombella R, Joshi T, Cheney C, Gowda A, Hayden-Ledbetter MS, Baum PR, Lin TS, Jarjoura D, Lehman A, Kussewitt D, Lee RJ, Caligiuri MA, Tridandapani S, Muthusamy N, Byrd JC.

Blood. 2007 Oct 1;110(7):2569-77. Epub 2007 Apr 17.

36.

Mild exercise training, cardioprotection and stress genes profile.

Marini M, Lapalombella R, Margonato V, Ronchi R, Samaja M, Scapin C, Gorza L, Maraldi T, Carinci P, Ventura C, Veicsteinas A.

Eur J Appl Physiol. 2007 Mar;99(5):503-10. Epub 2007 Jan 6.

37.

Sequential events of apoptosis involving docetaxel, a microtubule-interfering agent: a cytometric study.

Fabbri F, Carloni S, Brigliadori G, Zoli W, Lapalombella R, Marini M.

BMC Cell Biol. 2006 Jan 26;7:6.

38.

Heat shock response by EBV-immortalized B-lymphocytes from centenarians and control subjects: a model to study the relevance of stress response in longevity.

Marini M, Lapalombella R, Canaider S, Farina A, Monti D, De Vescovi V, Morellini M, Bellizzi D, Dato S, De Benedictis G, Passarino G, Moresi R, Tesei S, Franceschi C.

Exp Gerontol. 2004 Jan;39(1):83-90.

PMID:
14724068
39.

Interleukin-11 induces proliferation of human T-cells and its activity is associated with downregulation of p27(kip1).

Curti A, Tafuri A, Ricciardi MR, Tazzari P, Petrucci MT, Fogli M, Ratta M, Lapalombella R, Ferri E, Tura S, Baccarani M, Lemoli RM.

Haematologica. 2002 Apr;87(4):373-80.

Supplemental Content

Loading ...
Support Center